ArticleVirology journal2025
Nuclear keratin 6A upregulates human papillomavirus oncogene expression through TEAD1 interaction.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functional roles of Keratin 6A in disease pathogenesis across cancer and skin disorders.Experimental biology and medicine (Maywood, N.J.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHuman papillomavirus (HPV) oncogenes, E6 and E7, play a critical role in cervical carcinogenesis, and their expression is regulated by cellular transcription factors bound to the long control region (LCR) in the HPV genome. To elucidate the mechanisms of HPV-induced carcinogenesis, it is important to identify host factors that control the LCR in cervical cancer cells. We previously reported that the LCR-bound transcription factor TEAD1 is critical for HPV oncogene expression. Here, we aimed to elucidate the role of stress-responsive keratin 6A (K6A), a potential cofactor for TEAD1, in HPV oncogene expression.
methodsHPV16-positive cervical cancer cells were transfected with small interfering RNA (siRNA) or infected with a lentivirus expressing short hairpin RNA (shRNA) to downregulate the expression of K6A. HPV16 oncogene expression was examined by reverse transcription-quantitative polymerase chain reaction or Western blotting. Retroviral transduction was used to rescue the expression of K6A in K6A-depleted cells. Subcellular localization of K6A was analyzed by cellular fractionation followed by Western blotting. Chromatin immunoprecipitation (ChIP) assay was used to evaluate in vivo binding of K6A to the LCR. The physical interaction between K6A and TEAD1 was assessed by co-immunoprecipitation and fluorescence-based in vivo interaction assays.
resultsTransfection of siRNA against K6A decreased levels of HPV16 E6*I mRNA and E7 protein in cervical cancer cells. Lentiviral delivery of shRNA against K6A also reduced E7 protein level and suppressed cell growth. Conversely, ectopic expression of shRNA-resistant K6A in the K6A-depleted cells restored E7 expression, and further siRNA knockdown of TEAD1 in the K6A-rescued cells attenuated E7 expression. K6A was detected in the nuclear fraction of cervical cancer cells with a functional bipartite nuclear localization signal in its N-terminus. ChIP assay showed that nuclear K6A bound to the HPV16 LCR in vivo, partially depending on the presence of the TEAD transcription factors. Finally, protein-protein interaction assays confirmed the association of K6A with TEAD1 in the nucleus.
conclusionsNuclear K6A associates with the LCR via TEAD1 and upregulates HPV16 oncogene expression, thereby contributing to cervical cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.